Biovista Inc., Charlottesville, July 7, 2010:  Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning.

The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the all-important IP considerations, discusses the science and tools involved as well as the relevant regulatory authorities framework, makes the case for the economic potential and finally profiles the main companies that are presently active in the drug repositioning space.

“This report is a good read for those professionals who wish to get a to-the-point introduction to Drug Repositioning, why it makes sense, key issues and main players” said Dr Andreas Persidis, CEO of Biovista Inc. “We are happy to recommend it to those who are thinking of drug repositioning as a strategy for adding value to their existing IP assets or those who are looking for opportunities in therapeutic areas with unmet medical needs.”


About Biovista’s repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant unmet medical needs.  Biovista’s proprietary repositioning technology allows the company’s experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and very short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases.

For more information on this report click here

For more information, please contact:

Dr. Andreas Persidis at:


Biovista, Inc.